Fractyl Health, headquartered in Burlington, Massachusetts, focuses on treating metabolic diseases like type 2 diabetes and obesity with its Revita DMR System and Rejuva gene therapy. The company went public on February 2, 2024, and employs 102 full-time staff.
Jay David Caplan sold 65,000 shares of GUTS on 12 September at $2.90 per share, worth a total of $188K. They now own 30,484 GUTS shares, or a 68% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
